The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer

被引:225
|
作者
Nachmias, B [1 ]
Ashhab, Y [1 ]
Ben-Yehuda, D [1 ]
机构
[1] Hadassah Univ Hosp, Dept Hematol, IL-91120 Jerusalem, Israel
关键词
apoptosis; cancer; IAP; caspase; molecular targets;
D O I
10.1016/j.semcancer.2004.04.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Apoptosis is a crucial biological process that prevents uncontrolled cell proliferation and eliminates harmful cells. Resistance to apoptotic stimuli is a hallmark feature of various cancers. One of the mechanisms through which tumor cells are believed to acquire resistance to apoptosis is by overexpression of inhibitor of apoptosis proteins (IAPs). IAPs are a group of structurally related proteins that were initially identified in baculoviruses. Mammalian IAPs block apoptosis either by binding and inhibiting caspases or through caspase-independent mechanisms. This family of proteins has become increasingly prominent in the field of cancer biology. To date, overexpression of several IAPs has been detected in various cancers. This paper reviews the recent advances in the research of IAPs. The differential expression and the biological significance of each IAP in various cancer types will be discussed. Finally, we review the most recent advances in the research efforts aimed at using IAPs as potential targets for cancer therapy. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:231 / 243
页数:13
相关论文
共 50 条
  • [21] DANCR: an emerging therapeutic target for cancer
    Yan, Yuheng
    Shi, Qingmiao
    Yuan, Xin
    Xue, Chen
    Shen, Shen
    He, Yuting
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2020, 12 (07): : 4031 - 4042
  • [22] The proteasome - An emerging therapeutic target in cancer
    Mitchell, BS
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (26): : 2597 - 2598
  • [23] The Mitochondrion as an Emerging Therapeutic Target in Cancer
    Roth, Katherine G.
    Mambetsariev, Isa
    Kulkarni, Prakash
    Salgia, Ravi
    TRENDS IN MOLECULAR MEDICINE, 2020, 26 (01) : 119 - 134
  • [24] Proteasome as an emerging therapeutic target in cancer
    Zavrski, I.
    Kleeberg, L.
    Kaiser, M.
    Fleissner, C.
    Heider, U.
    Sterz, J.
    Jakob, C.
    Sezer, O.
    CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (05) : 471 - 485
  • [25] Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer
    Hariu, H
    Hirohashi, Y
    Torigoe, T
    Asanuma, H
    Hariu, M
    Tamura, Y
    Aketa, K
    Nabeta, C
    Nakanishi, K
    Kamiguchi, K
    Mano, Y
    Kitamura, H
    Kobayashi, J
    Tsukahara, T
    Shijubo, N
    Sato, N
    CLINICAL CANCER RESEARCH, 2005, 11 (03) : 1000 - 1009
  • [26] Comprehensive molecular characterization of inhibitors of apoptosis proteins (IAPs) for therapeutic targeting in cancer
    Liang, Jianfeng
    Zhao, Wanni
    Tong, Pan
    Li, Ping
    Zhao, Yuanli
    Li, Hua
    Liang, Jun
    BMC MEDICAL GENOMICS, 2020, 13 (01)
  • [27] Comprehensive molecular characterization of inhibitors of apoptosis proteins (IAPs) for therapeutic targeting in cancer
    Jianfeng Liang
    Wanni Zhao
    Pan Tong
    Ping Li
    Yuanli Zhao
    Hua Li
    Jun Liang
    BMC Medical Genomics, 13
  • [28] X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy
    Obexer, Petra
    Ausserlechner, Michael J.
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [29] The inhibitors of apoptosis (IAPs) as cancer targets
    Allison M. Hunter
    Eric C. LaCasse
    Robert G. Korneluk
    Apoptosis, 2007, 12 : 1543 - 1568
  • [30] Molecular characterization of an inhibitor of apoptosis protein (IAPs) in freshwater pearl mussel, Hyriopsis schlegelii
    Wu, Di
    Wang, Chengyuan
    Zhang, Wanchang
    Peng, Kou
    Sheng, Junqing
    Wang, Junhua
    Jain, Archana
    Hong, Yijiang
    BIOENGINEERED, 2019, 10 (01) : 365 - 373